SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Dr Reddy's Laboratories Limited logo
2 months ago

Consumer Health Brand Marketing Intern

Dr Reddy's Laboratories Limited

Princeton, NJ (Hybrid)Full time
Dr Reddy's Laboratories Limited logo
4 months ago

Lead Digital & Performance Marketing

Dr Reddy's Laboratories Limited

Princeton, NJ (On-site)Full time
Dr Reddy's Laboratories Limited logo
4 months ago

Brand & Ecommerce Manager - Women's Wellness (Consumer Health)

Dr Reddy's Laboratories Limited

Princeton, NJ (Hybrid)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Dr Reddy's Laboratories Limited logo

Consumer Health Brand Marketing Intern

Dr Reddy's Laboratories Limited

Princeton, NJ (Hybrid)

In-houseFull-timeIntern/new grad
2 months ago
Dr Reddy's Laboratories Limited logo

Lead Digital & Performance Marketing

Dr Reddy's Laboratories Limited

Princeton, NJ (On-site)

In-houseFull-timeSenior level6+ years exp.
4 months ago
Dr Reddy's Laboratories Limited logo

Brand & Ecommerce Manager - Women's Wellness (Consumer Health)

Dr Reddy's Laboratories Limited

Princeton, NJ (Hybrid)

In-houseFull-timeMid level5+ years exp.
4 months ago
Dr Reddy's Laboratories Limited logo
Dr Reddy's Laboratories Limited

Consumer Health Brand Marketing Intern

Princeton, NJ (Hybrid)

Salary Not AvailableIntern/New GradFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Support the end-to-end execution of digital brand and product storytelling, turning consumer insights into compelling content and compliant marketing assets across Amazon, retailer.com, and D2C sites.

  • Content & Brand Storytelling: Create original content, craft messaging rooted in empathy, and assemble brand assets and claims repository.
  • Asset Library & Compliance: Develop a brand asset library and coordinate with legal/regulatory to ensure content accuracy and regulatory alignment.
  • Market Insights & Launch Analytics: Gather consumer data, trends, and testing results to inform go-to-market plans and new product launches.

Job Description

  • Responsibilities - Help the team with the execution and analysis of digital strategies to create consumer demand across Amazon, retailer.com and D2C sites
  • Assist with the development of a brand asset library
  • Lead development of a claims repository
  • Help craft compelling brand stories & product messaging rooted in empathy and cultural relevance
  • Create and edit original content
  • Collaborate with legal/regulatory to ensure content accuracy & compliance
  • Sales Analysis: Create and execute reporting for new product launches
  • Consumer & Market Research: Gather consumer insights, data, research, category trends and best practices to input into strategic plans; Assist with consumer testing of new ideas
  • Other duties as assigned
Dr Reddy's Laboratories Limited logo

Dr Reddy's Laboratories Limited

3.9 Glassdoor

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by:Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to complianceofficer@drreddys.com or chiefombudsperson@drreddys.com. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Founded in 1984
Hyderabad, Telangana, IND
32K employees (622 in marketing)
www.drreddys.com
80% recommend to a friend
88% CEO approval

Traffic Signals

Monthly Visitors
118.8K
Monthly Google Ads Budget
$547
Traffic Source Mix
Search
55.1%
Direct
35.1%
Referral
6.1%
Social
2.6%
Paid
1%

Headcount Trend

Current headcount: ~31.8K

Marketing Team

Marketing Team Size
622 (2% of company)

Funding

Total Funding
$6M
Last Raise
$6M
Post IPO Equity, 9 months ago

Funding History

  • Jun 2025
    Post IPO Equity
  • Oct 2022
    Post IPO Equity
  • Dec 2001
    Post IPO Equity • $6M

Recent News

Dr Reddy's Labs decline 6% after getting non-compliance notice from Canada
Oct 30, 2025 • Fortune India
Dr Reddy's Labs falls 6% after firm gets non-compliance notice for semaglutide in Canada
Oct 30, 2025 • Moneycontrol
Dr. Reddy's Laboratories shares fall over 4% after delay in approval for key drug
Oct 30, 2025 • CNBC TV18
Dr Reddys ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle
Oct 29, 2025 • NDTV Profit
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History
Oct 29, 2025 • The Economic Times
Dr Reddy's Faces Regulatory Hurdle in Canada for Semaglutide Submission
Oct 29, 2025 • scanx.trade
Dr Reddy's Laboratories Hits Day Low Amid Price Pressure, Falls to Rs 1242.75
Oct 29, 2025 • Markets Mojo
Dr Reddy’s warns of 'huge monetary loss' in plea against FSSAI order on ORS
Oct 29, 2025 • Moneycontrol
Sanjay Sharma takes on additional responsibilities as CHRO at Dr Reddy’s
Oct 27, 2025 • People Matters India
Dr Reddy’s Laboratories Q2 Results: Net Profit Rises 7% YoY to Rs 1,347 Cr; Revenue Up 10% Amid US Competition
Oct 24, 2025 • Goodreturns
Dr Reddy’s Q2 Results | Net profit up 7%, revenue climbs 10% to ₹8,828 crore; beats estimates
Oct 24, 2025 • CNBC TV18
Dr Reddy's Q2FY26 results: Profit up 14% at ₹1,437.2 cr, revenue jumps 10%
Oct 24, 2025 • Business Standard
Dr Reddy's Laboratories Q2 Results: Profit rises 7% YoY to Rs 1,347 crore, revenue up 10%
Oct 24, 2025 • The Economic Times
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
Oct 24, 2025 • Moneycontrol
Dr Reddy’s Q2 Preview: PAT may grow up to 11–18% YoY; revenue seen steady despite pricing pressure in US
Oct 23, 2025 • The Economic Times
Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates
Oct 23, 2025 • Business Standard
LIC stake in Dr. Reddy’s races past 10%
Oct 17, 2025 • The Hindu
Zydus, Dr Reddy's recall products in US over manufacturing issues
Oct 13, 2025 • Medical Dialogues
Dr. Reddy's Laboratories Faces Mixed Technical Indicators Amid Market Evaluation Changes
Oct 13, 2025 • Markets Mojo
Dr. Reddy's and Zydus Recall Pharmaceutical Products in US Market
Oct 12, 2025 • scanx.trade
Dr Reddy's, Zydus recall products in US over manufacturing issues: USFDA
Oct 12, 2025 • Business Standard
Dr. Reddy's Laboratories - Negative Breakout: These 9 stocks close cross below their 200 DMAs
Oct 9, 2025 • The Economic Times
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History
Sep 24, 2025 • The Economic Times
Dr. Reddy’s, Hetero to supply Gilead’s HIV drug Lenacapavir at $40
Sep 24, 2025 • The Hindu
Dr Reddy's Labs receives positive EMA Committee opinion for proposed biosimilar of Prolia, Xgeva
Sep 23, 2025 • Medical Dialogues
EMA panel recommends marketing nod for Dr. Reddy’s biosimilar
Sep 22, 2025 • The Hindu
Dr. Reddy's Laboratories Adjusts Technical Outlook Amid Strong Financial Performance
Sep 22, 2025 • Markets Mojo
GLP-1 drugs on WHO Essential Medicines List: what’s the impact?
Sep 19, 2025 • Labiotech UG
Despite Muted US Exports, Pharma co.s to Grow 10 PC
Sep 19, 2025 • Deccan Chronicle
Dr. Reddy's Promoters Transfer 20.58% Stake to Family Trusts for Succession Planning
Sep 18, 2025 • scanx.trade
Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiry
Sep 17, 2025 • The Economic Times
Will legal troubles in the US weigh on India’s obesity drug boom?
Sep 17, 2025 • Livemint.com
Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiry
Sep 17, 2025 • IndiaTimes
Stocks to watch: RailTel, Coal India, Apollo Tyres, BEL among shares in focus today
Sep 17, 2025 • Livemint.com
HK inno.N’s reflux therapy hits Indian market
Sep 17, 2025 • Korea Herald
Stocks to Watch today: Urban Company, Akzo Nobel, BEL, One Mobikwik, DRL
Sep 17, 2025 • Business Standard India
Dr Reddy's launches 'Tegoprazan' in India for acid peptic diseases
Sep 16, 2025 • Business Standard
Dr. Reddy’s introduces Korean firm HK inno.N’s APD drug Tegoprazan in India
Sep 16, 2025 • The Hindu
Dr Reddy’s launches Tegoprazan for treatment of acid-related disorders in Indian market
Sep 16, 2025 • Hindu Business Line
Dr Reddy's Laboratories Receives FDA Form 483 with Five Observations at Bachupally Biologics Facility
Sep 15, 2025 • scanx.trade
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History
Sep 15, 2025 • The Economic Times
Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?
Sep 15, 2025 • Business Standard India
Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations
Sep 15, 2025 • Business Standard India
Dr. Reddy’s Biologics facility gets 5 observations from FDA
Sep 14, 2025 • ETPharma.com
Dr Reddy’s Bachupally facility gets 5 observations from US FDA inspection
Sep 13, 2025 • CNBC TV18
Dr Reddys Labs gets 5 observations from USFDA for Bachupally facility
Sep 13, 2025 • Medical Dialogues
Dr. Reddy's Receives Form 483 with Five Observations Following USFDA Inspection at Hyderabad Biologics Facility
Sep 13, 2025 • scanx.trade
U.S. FDA issues 5 observations to Dr. Reddy’s biologics manufacturing facility in Hyderabad
Sep 13, 2025 • The Hindu
Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, Torrent Pharma et al: Parsing through the pharma value chain
Sep 13, 2025 • Hindu Business Line
Recent uptick might appease Dr. Reddy's Laboratories Limited (NSE:DRREDDY) institutional owners after losing 1.9% over the past year
Sep 12, 2025 • simplywall.st
Stocks to buy for short term: From HAL to Bharti Airtel— Ajit Mishra of Religare Broking recommends THESE 3 shares
Sep 12, 2025 • Livemint.com
Dr. Reddy’s Buys STUGERON Portfolio for $50.5M Expansion
Sep 11, 2025 • HDFC Sky
Dr. Reddys Acquires J&Js Stugeron Portfolio For Rs 445 Crore, Enters Anti-Vertigo Segment
Sep 11, 2025 • NDTV Profit
Dr. Reddy's acquires J&J's Stugeron brand for $50.5 million
Sep 11, 2025 • Moneycontrol
Dr. Reddy's shares in focus after $50.5 million acquisition marking anti-vertigo foray
Sep 11, 2025 • CNBC TV18
Dr Reddy's signs pact with J&J to acquire vertigo treatment brand
Sep 11, 2025 • Business Standard
Dr Reddy’s acquires J&J CNS brands 18 market rights for over $50 million
Sep 11, 2025 • ETPharma.com
Stocks to watch today, Sep 11: Bajaj Finserv, DRL, Mazagon, Jupiter Wagons
Sep 11, 2025 • Business Standard India
Dr Reddy’s enters anti-vertigo segment with acquisition of Stugeron from Johnson & Johnson
Sep 11, 2025 • Hindu Business Line
Dr Reddy’s shares slip nearly 2% on investor concerns amid $50 million foray into anti-vertigo category
Sep 11, 2025 • IndiaTimes
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Sep 10, 2025 • MarketScreener
Stocks to buy today: Ankush Bajaj's top three recommendations for 10 September
Sep 10, 2025 • Livemint.com
Sensex rises 300 points, Nifty 50 ends above 24,850— 10 key highlights from Indian stock market today
Sep 9, 2025 • Livemint.com
Indian pharma sector needs price hikes, site and IP transfers to tackle US tariff uncertainty: Report
Sep 9, 2025 • Livemint.com
Dr Reddy's Labs UK facility flagged with 7 USFDA observations
Sep 8, 2025 • Business Standard
India's stock benchmarks to open higher on GST cuts, US rate cut hopes
Sep 8, 2025 • Reuters
Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations
Sep 6, 2025 • Medical Dialogues
Dr Reddy's Laboratories May Benefit from Potential GST Exclusion on Cancer Medications
Sep 3, 2025 • scanx.trade
PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies
Sep 3, 2025 • PRISM MarketView
Dr. Reddy's Laboratories CHRO Archana Bhaskar resigns
Sep 2, 2025 • People Matters India
Sensex, Nifty 50 fall on fag-end profit booking— 10 key highlights from the Indian stock market today
Sep 2, 2025 • Livemint.com
Sun Pharma stock slips 2% in firm market, nears 52-week low; here's why
Sep 1, 2025 • Business Standard India
Stocks to watch: IndiGo, Tata Steel, United Breweries, Oil India among shares in focus today
Aug 28, 2025 • Livemint.com
Coya Therapeutics to progress trial of ALS treatment upon FDA approval
Aug 28, 2025 • Pharma Times
Dr Reddy's launches novel drug for chronic constipation management
Aug 26, 2025 • The Economic Times
Dr Reddy’s launches constipation drug in India
Aug 26, 2025 • ETPharma.com
Dr Reddy's expects new GST framework to address critical issues impacting pharma sector
Aug 26, 2025 • IndiaTimes
Dr Reddy's launches novel drug for chronic constipation management
Aug 26, 2025 • Business Standard India
Pharma industry hopes for relief from GST reforms
Aug 26, 2025 • The Hindu
Dr Reddy’s launches drug for treatment of chronic constipation
Aug 26, 2025 • Hindu Business Line
Optimistic on GST reforms for pharmaceutical sector: Dr Reddy’s Chairman Satish Reddy
Aug 26, 2025 • Hindu Business Line
Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?
Aug 26, 2025 • Business Standard India
Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access
Aug 26, 2025 • Business Standard India
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
Aug 25, 2025 • prnasia.com
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Aug 25, 2025 • BioSpace
Earnings Working Against Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Share Price
Aug 22, 2025 • simplywall.st
Deoxyribonucleic Acid (DNA) Repair Alkylating Agent Market to Reach US $5.05 Billion by 2029
Aug 21, 2025 • EIN Presswire
Natco Pharma sues Novo Nordisk in generic drug push
Aug 21, 2025 • IndiaTimes
Sensex, Nifty rise for 6th consecutive session— 10 key highlights from the Indian stock market today
Aug 21, 2025 • Livemint.com
Oncology Biosimilars Market to Hit USD 24 Billion by 2035 | Sandoz, Pfizer, Celltrion Lead – Fact.MR
Aug 20, 2025 • EIN Presswire
Sensex, Nifty 50 rise for 4th consecutive session— 10 key highlights from the Indian stock market today
Aug 19, 2025 • Livemint.com
Indian markets close higher on GST reform hopes, Russia-Ukraine peace developments
Aug 19, 2025 • Taiwan Sun
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cre
Aug 19, 2025 • PharmiWeb
FMCG in a sweet spot after GST cuts and monsoon boost: Rajat Sharma
Aug 19, 2025 • IndiaTimes
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
Aug 18, 2025 • Extrovis AG
Dr Reddy's Secures CDSCO Panel Approval to Import, Market Olutasidenib for AML
Aug 17, 2025 • Medical Dialogues
Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take note
Aug 17, 2025 • IndiaTimes
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth
Aug 14, 2025 • Research and Markets
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Aug 14, 2025 • BioSpace
Mixed Q1 results for top drug firms amid price erosion, tariff threat
Aug 13, 2025 • Business Standard India